Spotlight December 2021 Archives - Page 2 of 3

Adherence In Schizophrenia: A Patient & Caregiver Perspective

Interview October 28, 2021

Kathy Day, Patient & Caregiver Section Advisor, sits down with Dennis Sholler from the field medical affairs team to discuss adherence in schizophrenia from a patient and caregiver perspective. Kathy… Read More

Increasing Medicare LTSS Benefits Could Cost Between $1 Billion & $13 Billion Per Year

Article October 25, 2021

Increasing access to long-term services and supports (LTSS) through the Medicare program for beneficiaries aged 65 and older could cost the federal government from $1.1 billion to $12.8 billion per… Read More

The Next Crisis: Major Depressive Disorder (MDD) Post Pandemic

Infographic October 22, 2021

Substance Use During The Covid-19 Pandemic

Infographic October 22, 2021

PsychU Q&A: What Is The Difference Between Schizophrenia & Schizoaffective Disorder?

Article October 14, 2021

Submitted Question: What is the difference between schizophrenia and schizoaffective disorder? Answer: Similarities exist in the presentation, diagnosis and treatment of schizophrenia and schizoaffective disorder that may contribute to the… Read More

Perspectives Of Schizophrenia Treatment Guidelines

On-Demand Webinar October 13, 2021

Schizophrenia is a challenging diagnosis both domestically and across the world. Various treatment guidelines have been developed by key thought leaders to share perspectives on acute and long-term management of… Read More

Schizophrenia Cost The U.S. $281.6 Billion In 2020; $62 Billion In Direct Costs

Article September 27, 2021

During 2020, the costs of schizophrenia in the United States was estimated at $281.6 billion. About 22% ($62.0 billion) of the total cost was due to direct health and human… Read More

Long-Acting Injectable Antipsychotics Now Easier To Find Closer To Home

Article August 19, 2021

During their 2021 legislative sessions, both Maryland and North Carolina enacted bills to allow pharmacists to administer long-acting injectable antipsychotics (LAIA) and other injectable drugs to consumers with a doctor’s… Read More

Maryland & North Carolina Implementing New Laws To Permit Pharmacists To Administer Long-Acting Injectable Antipsychotics

Article July 19, 2021

During their 2021 legislative sessions, both Maryland and North Carolina enacted bills to allow pharmacists to administer long-acting injectable (LAI) antipsychotics and injectable drugs to consumers with a prescription. In… Read More

63% Of People With Schizophrenia Take Medications Raising Risk Of Cognitive Impairment

Article June 28, 2021

About 63% of people with schizophrenia take medications with anticholinergic properties associated with cognitive impairment. Anticholinergics are substances that block the action of the neurotransmitter called acetylcholine at synapses in… Read More

Now Leaving PsychU

This link will take you outside of the PsychU community website

PsychU

Sorry, this content is no longer available.

Stay Connected: